Seasoned CAR T executive to lead Leucid’s corporate strategy built around its proprietary lateral CAR platform LONDON, July 18, 2023 /PRNewswire/ — Leucid Bio (“Leucid” or the “Company”), a biotech company pursuing a differentiated approach to develop next generation Chimeric Antigen…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.